Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
JICC01 - Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC
- 07:00 - 09:00
- 1/28/2021
- Location: Scientific Program Auditorium
- Not for CME Credit
- Type: Workshop
- Track: N.A.
-
+
JICC01.08 - Target Driver Gene and Target VEGFR: Could Prolong OS?
07:45 - 08:00 | Presenter: Ying Cheng
- Abstract
No abstract available for this presentation
-
+
FP14 - Targeted Therapy - Clinically Focused
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Targeted Therapy - Clinically Focused
-
+
FP14.12 - Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3.
00:00 - 00:00 | Presenter: Yi-long Wu
- Abstract
Loading...
-
+
P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
P01.05 - Pilot Study of Inhaled Azacitidine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Haiying Cheng
- Abstract
Loading...
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P09.03 - Thyroid Dysfunction in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors (ICI): Outcomes in a Multiethnic Urban Cohort.
00:00 - 00:00 | Presenter: Angelica D'Aiello
- Abstract
Loading...
-
+
P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P14.17 - Low BMI is Associated with Inferior Overall Survival in HIV Patients with Advanced NSCLC Undergoing Immunotherapy
00:00 - 00:00 | Presenter: Emily Lin
- Abstract
Loading...
-
+
P33 - Pathology - Immunotherapy Biomarker
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
-
+
P33.09 - Tumor Mutational Burden in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy: Outcomes in a Multiethnic Cohort
00:00 - 00:00 | Presenter: Laura Sofia Munoz-Arcos
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.67 - Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
00:00 - 00:00 | Presenter: Adam Pluzanski
- Abstract
Loading... -
+
P76.77 - Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations
00:00 - 00:00 | Presenter: Weineng Feng
- Abstract
Loading...
-
+
P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P78.03 - Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC
00:00 - 00:00 | Presenter: Cheng Huang
- Abstract
Loading...
-
+
P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P79.02 - Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLC
00:00 - 00:00 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
P79.08 - Sintilimab ± IBI305 Plus Chemotherapy for Patients With EGFR-Mutant Non-Squamous NSCLC Failed to EGFR-TKI Treatment
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading...
-
+
P83 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Targeted Therapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P83.01 - Updated Survival and Biomarker Analysis of Camrelizumab and Apatinib in Previously Treated pts of Advanced Non-Squamous NSCLC
00:00 - 00:00 | Presenter: Shengxiang Ren
- Abstract
Loading...